Potential New Therapies for the Treatment of HIV-1 Infection
- 1 February 2002
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 541-555
- https://doi.org/10.1146/annurev.med.53.082901.104110
Abstract
▪ Abstract The development and clinical use of chemotherapeutic agents for the treatment of persistent HIV-1 infection over the past decade has profoundly and favorably affected the course of HIV-1 disease for many infected individuals. Unfortunately, the long-term use of these therapies is complicated by unwanted metabolic side effects, by issues of adherence, and by the selection of viral variants with reduced susceptibility. These complications have spurred the search for new anti-HIV-1 agents having improved pharmacological properties and expressing activity against viral variants resistant to the currently available agents. This brief review describes the current state of this search as well as potentially novel viral targets for chemotherapeutic intervention.Keywords
This publication has 46 references indexed in Scilit:
- Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140Journal of Virology, 2001
- Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 StudyThe Journal of Infectious Diseases, 2000
- Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected AdultsThe Journal of Infectious Diseases, 2000
- Deletion of the GPG Motif in the HIV Type 1 V3 Loop Does Not Abrogate Infection in All CellsAIDS Research and Human Retroviruses, 2000
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- HIV Entry and Its InhibitionPublished by Elsevier ,1998
- HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled ReceptorScience, 1996
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Structure of influenza haemagglutinin at the pH of membrane fusionNature, 1994
- A spring-loaded mechanism for the conformational change of influenza hemagglutininCell, 1993